Angiogenesis Pathway

Introduction

Angiogenesis is the process of forming new blood vessels from existing ones, critical for brain function and heavily implicated in neurodegenerative diseases. This pathway regulates cerebral blood flow, blood-brain barrier maintenance, and neurovascular coupling—all essential for neuronal health and function. ^{5Greenberg DA, Jin K (2005) "Vascular endothelial growth factors and angiogenesis in the nervous system." *Annals of Neurology*2005 · Annals of Neurology · PMID 15729152Open reference}

In the adult brain, angiogenesis is tightly regulated under normal conditions but becomes dysregulated in Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative conditions. The neurovascular unit, comprising endothelial cells, pericytes, astrocytes, and neurons, coordinates angiogenic processes essential for brain homeostasis. ^{6'(2013) "Angiogenesis in the nervous system: developmental and pathological mechanisms." *Brain Research*'2013 · Brain Research · PMID 23770307Open reference}

Overview

| Property | Value | ^{7'(2020) "Angiogenesis in Alzheimer''s disease: novel biomarkers and therapeutic targets." *Journal of Cerebral Blood Flow & Metabolism*'2020 · Journal of Cerebral Blood Flow & Metabolism · PMID 32838562Open reference} |----------|-------| ^{8'(2019) "VEGF-mediated angiogenesis in the CNS: a double-edged sword." *Nature Reviews Neuroscience*'2019 · Nature Reviews Neuroscience · PMID 31222132Open reference} | Process | New blood vessel formation from existing vasculature | ^{9'(2018) "The role of VEGF in the neurovascular unit: implications for neurodegenerative diseases." *Journal of Neuroinflammation*'2018 · Journal of Neuroinflammation · PMID 30594278Open reference} | Primary Regulator | Vascular Endothelial Growth Factor (VEGF) | ^{10'(2021) "Pericyte dysfunction in Alzheimer''s disease: role in amyloidogenesis." *Acta Neuropathologica*'2021 · Acta Neuropathologica · PMID 33828563Open reference} | Adult Brain Status | Limited under normal conditions; reactivated in pathology | ^{2CitationPMID 41338464Open reference}0 | Key Cell Types | Endothelial cells, pericytes, vascular smooth muscle cells, astrocytes | ^{2CitationPMID 41338464Open reference}1 | Brain Regions Affected | Cortex, hippocampus, substantia nigra, basal ganglia | ^{2CitationPMID 41338464Open reference}2

Molecular Pathway

VEGF Signaling Cascade

The VEGF signaling pathway is the primary driver of angiogenesis in the brain: ^{2CitationPMID 41338464Open reference}3

1. VEGF Release - Induced by hypoxia (HIF-1α activation), injury, inflammation, or metabolic stress

2. VEGFR2 Dimerization - VEGF-A binds to VEGFR2 on endothelial cells, causing receptor dimerization and autophosphorylation

3. Downstream Signaling Cascades:

   • PI3K/AKT Pathway - Mediates endothelial cell survival, nitric oxide production, and vascular permeability

   • MAPK/ERK Pathway - Drives endothelial cell proliferation and differentiation

   • Src Pathway - Regulates vascular permeability and cytoskeletal reorganization

   • FAK Pathway - Controls cell adhesion, migration, and vessel maturation

4. Endothelial Cell Activation - Upregulation of integrins, proteases (MMPs), and growth factors

5. Matrix Remodeling - MMP-mediated degradation of basement membrane

6. Sprouting Angiogenesis - Formation of new vessel sprouts via tip cells and stalk cells

7. Vessel Maturation - Pericyte recruitment via PDGF-B/PDGFR-β signaling

8. Lumen Formation - Cord hollowing and tube formation

Key Molecular Players

VEGF Isoforms and Brain Distribution

The VEGF family includes multiple isoforms with distinct functions:

VEGF-A further splices into VEGF121, VEGF165, and VEGF189 variants:

• VEGF121: Freely diffusible, minimal heparin binding

• VEGF165 (most common): Balanced between diffusible and heparin-bound

• VEGF189: Predominantly cell-associated, highest heparin binding

Role in Neurodegeneration

Alzheimer’s Disease

Angiogenesis and vascular dysfunction play critical roles in Alzheimer’s disease pathology:

Vascular Hypoperfusion

• Reduced cerebral blood flow (CBF) observed in early AD

• Contributes to amyloid-beta (Aβ) clearance impairment

• Neuronal hypoxia promotes Aβ production via HIF-1α

• White matter lesions from chronic hypoperfusion

Aβ-VEGF Interaction

• Aβ directly inhibits VEGF signaling

• Aβ induces endothelial cell dysfunction

• VEGF counteracts Aβ-induced neurotoxicity (protective)

• Therapeutic angle: balance VEGF signaling

Angiogenic Paradox

• Some neovascularization may be beneficial (improved perfusion)

• Pathological angiogenesis can increase BBB permeability

• Cerebral amyloid angiopathy (CAA) involves vessel damage

• Need for precise temporal/spatial targeting

Neurovascular Unit Dysfunction

• Pericyte loss in AD brains (correlation with cognitive decline)

• BBB breakdown increases Aβ deposition

• Astrocyte endfoot degeneration disrupts neurovascular coupling

• Reduced coverage of endothelial cells by pericytes

Parkinson’s Disease

Vascular contributions to Parkinson’s disease include:

Cerebral Blood Flow Alterations

• Reduced CBF in frontal cortex and substantia nigra

• Vascular rarefaction in substantia nigra pars compacta

• Correlation between vascular risk factors and PD severity

VEGF Dysregulation

• Elevated VEGF in PD CSF (compensatory?)

• Impaired VEGF signaling in substantia nigra

• VEGF neuroprotection studies in animal models

BBB Changes

• Increased BBB permeability in PD

• Altered pericyte function

• Leukocyte infiltration in substantia nigra

Other Neurodegenerative Conditions

Vascular Cognitive Impairment (VCI)

• Second most common cause of dementia

• Multi-infarct dementia from multiple small vessel strokes

• Binswanger’s disease (subcortical leukoaraiosis)

• Mixed AD/VCI pathology common

Amyotrophic Lateral Sclerosis (ALS)

• Motor cortex hypoperfusion

• VEGF dysregulation in ALS patients

• SOD1 mice show impaired VEGF signaling

• Clinical trials of VEGF gene therapy

Huntington’s Disease

• Reduced cerebral blood flow

• VEGF-A expression changes

• Angiogenic factor alterations in HD models

Mermaid Diagram

Therapeutic Targeting

VEGF-Based Therapies

VEGF-Independent Angiogenesis Pathways

Novel Therapeutic Approaches

Combination Therapies

• VEGF therapy + anti-amyloid approaches

• Angiopoietin-1 mimetics for vessel stabilization

• Pericyte-targeting compounds

BBB-Penetrant Approaches

• Small molecule VEGFR inhibitors

• Peptide-based VEGF modulators

• Cell-penetrant VEGF receptor agonists

Gene Therapy

• AAV-mediated VEGF expression

• CRISPR-based VEGF regulation

• Ex vivo endothelial cell modification

Clinical Trials

Biomarkers Related to Angiogenesis

Background

The study of Angiogenesis Pathway has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Cross-References

Related Mechanisms

• Neurovascular Unit

• Blood-Brain Barrier

• Cerebral Hypoperfusion

• Amyloid Cascade

• Neuroinflammation

• Mitochondrial Dysfunction

Related Proteins

• VEGF Protein

• VEGFR2 Protein

• Ang-1 Protein

• Ang-2 Protein

• Tie2 Protein

• PDGF-B Protein

Related Diseases

• Alzheimer’s Disease

• Parkinson’s Disease

• Vascular Dementia

• Vascular Cognitive Impairment

• Amyotrophic Lateral Sclerosis

Related Cell Types

• Endothelial Cells

• Pericytes

• Astrocytes

• Neural Stem Cells

Recent Research Updates (2024-2026)

Recent publications:

1. Pericyte-glial cell interactions: Insights into brain health and disease. (2026) — Neural regeneration research ^{1CitationPMID 40537003Open reference}(https://pubmed.ncbi.nlm.nih.gov/40537003/)

2. Exosome therapy protects the hippocampus in mice exposed to chronic methamphetamine. (2026) — Neuropharmacology ^{2CitationPMID 41338464Open reference}(https://pubmed.ncbi.nlm.nih.gov/41338464/)

3. Cerebrovascular Unit Activation and Response Following Traumatic Brain Injury. (2026) — Shock ^{3CitationPMID 41166163Open reference}(https://pubmed.ncbi.nlm.nih.gov/41166163/)

4. Microbiota-gut-brain axis and probiotics: potential therapeutic strategies for treating Alzheimer’s disease. (2026) — Nutritional neuroscience ^{4CitationPMID 41074715Open reference}(https://pubmed.ncbi.nlm.nih.gov/41074715/)

See Also

• Blood-Brain Barrier

• Neurovascular Unit

• VEGF Protein

• Cerebral Hypoperfusion

• Alzheimer’s Disease Mechanisms

• Parkinson’s Disease Mechanisms

• Vascular Dementia

Pathway Diagram

The following diagram shows the key molecular relationships involving Angiogenesis Pathway discovered through SciDEX knowledge graph analysis:

graph TD
    STAT3["STAT3"] -->|"regulates"| angiogenesis["angiogenesis"]
    VEGFA["VEGFA"] -->|"promotes"| angiogenesis["angiogenesis"]
    FGF2["FGF2"] -->|"promotes"| angiogenesis["angiogenesis"]
    VEGF_B["VEGF-B"] -.->|"inhibits"| angiogenesis["angiogenesis"]
    FGF2_mutant__K119E_R120E_K125E["FGF2 mutant (K119E/R120E/K125E)"] -.->|"suppresses"| angiogenesis["angiogenesis"]
    HIF1A["HIF1A"] -->|"promotes"| angiogenesis["angiogenesis"]
    MTOR["MTOR"] -->|"promotes"| angiogenesis["angiogenesis"]
    MIR130A["MIR130A"] -->|"regulates"| angiogenesis["angiogenesis"]
    PI3K_AKT_MTOR["PI3K/AKT/MTOR"] -->|"promotes"| angiogenesis["angiogenesis"]
    ERK["ERK"] -->|"promotes"| angiogenesis["angiogenesis"]
    IL_6["IL-6"] -->|"modulates"| angiogenesis["angiogenesis"]
    extracellular_vesicles["extracellular vesicles"] -->|"promotes"| angiogenesis["angiogenesis"]
    TGFB1["TGFB1"] -->|"promotes"| angiogenesis["angiogenesis"]
    PI3K_AKT_mTOR["PI3K/AKT/mTOR"] -->|"promotes"| angiogenesis["angiogenesis"]
    RAS_PI3K_interaction_disruptio["RAS-PI3K interaction disruption"] -->|"prevents"| angiogenesis["angiogenesis"]
    style STAT3 fill:#4fc3f7,stroke:#333,color:#000
    style angiogenesis fill:#4fc3f7,stroke:#333,color:#000
    style VEGFA fill:#ce93d8,stroke:#333,color:#000
    style FGF2 fill:#4fc3f7,stroke:#333,color:#000
    style VEGF_B fill:#4fc3f7,stroke:#333,color:#000
    style FGF2_mutant__K119E_R120E_K125E fill:#4fc3f7,stroke:#333,color:#000
    style HIF1A fill:#ce93d8,stroke:#333,color:#000
    style MTOR fill:#ce93d8,stroke:#333,color:#000
    style MIR130A fill:#ce93d8,stroke:#333,color:#000
    style PI3K_AKT_MTOR fill:#81c784,stroke:#333,color:#000
    style ERK fill:#4fc3f7,stroke:#333,color:#000
    style IL_6 fill:#4fc3f7,stroke:#333,color:#000
    style extracellular_vesicles fill:#80deea,stroke:#333,color:#000
    style TGFB1 fill:#4fc3f7,stroke:#333,color:#000
    style PI3K_AKT_mTOR fill:#81c784,stroke:#333,color:#000
    style RAS_PI3K_interaction_disruptio fill:#4fc3f7,stroke:#333,color:#000